The new rapid diagnostic method allows enables to collect their own saliva samples, reducing the risk of Covid-19 infection among healthcare workers. Credit: Governor Tom Wolf.

Japanese pharmaceutical company Shionogi has signed a licensing agreement with Nihon University, Gunma University and Tokyo Medical University for a new rapid diagnostic method for viruses, including coronavirus (Covid-19).

The test uses a viral rapid diagnostic method and signal amplification by ternary initiation complexes method (SATIC method). The method was developed by the joint research team, consisting of Nihon University, Gunma University and Tokyo Medical University.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The method allows determining the presence or absence of SARS-CoV-2 or influenza virus without a detector. It also enables the detection of viruses from saliva and sputum, along with nasopharyngeal swabs.

The patient will be able to collect their own saliva samples, reducing the risk of infection among healthcare workers associated with specimen collection.

In addition, the results can be delivered in approximately 25 minutes after sample collection.

The company noted that the accuracy of the tests is equivalent to those by polymerase chain reaction (PCR) tests.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The use of the test method is expected to enable the diagnosis of Covid-19 in patients without symptoms more quickly and conveniently. Patients would also benefit from early diagnosis-based preventive measures against aggravation and early administration of treatment drugs.

Shionogi noted that it will work closely with the government, industry and the universities to quickly market the new rapid diagnostic method to contain the pandemic.

Earlier this month, Shionogi launched IgG/IgM Antibody-test Kit for Covid-19 as a research reagent to detect the number of SARS-CoV-2-infected patients.